Danaher Corporation (DHR)
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Danaher Q1 2026 Earnings Update
Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q'26. Life Sciences segment's core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q'25.
Danaher Q1 Earnings Call Highlights
Danaher (NYSE: DHR) reported first-quarter 2026 sales of $6.0 billion, with core revenue up 0.5% year over year as strength in bioprocessing and better-than-expected life sciences performance largely offset a lighter-than-normal respiratory season at Cepheid. President and CEO Rainer Blair said the company delivered "better than expected adjusted EPS growth" by "leveraging the Danaher Business System
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR beats Q1 EPS estimates and lifts 2026 outlook, but revenues miss as Diagnostics lags while bioprocessing strength and Masimo deal shape growth plans.
LH or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock
Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2026 sales of $5.95 billion, up 3.5% year-over-year, but under the consensus of $5.99 billion. Core revenue increased 0.5% year-over-year.
Danaher Corporation (DHR) Q1 2026 Earnings Call Transcript
Danaher Corporation (DHR) Q1 2026 Earnings Call Transcript
Danaher (DHR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?
DHR heads into Q1 results with rising bioprocessing demand and steady estimates, but cost pressures and FX headwinds could weigh on performance.
Ahead of Danaher (DHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors
Danaher is an American healthcare company that manufactures and markets products used for advances in biotechnology, life sciences, and diagnostics. Danaher has increased its dividend for 13 consecutive years. And its dividend growth has been nothing short of spectacular. DHR has a strong financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.
